CA-THERMO-FISHER
Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union. These compliance updates will enable cytogenetics testing laboratories to adapt to the latest medical device safety and efficacy frameworks and conformity assessments.
“Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and general manager, microarray, at Thermo Fisher Scientific. “The compliance updates to the CytoScan Dx Assay kit and ChAS Dx software provide our customers in the EU with solutions that can help them maintain high patient safety standards and meet EU IVD regulatory requirements.”
Advancements in chromosomal microarrays (CMAs) have greatly expanded the capabilities of cytogenetics testing in recent years, including the ability to yield insights into genetic risk factors and disorders that are essential to understanding reproductive health. As an in vitro diagnostic CMA test for postnatal analysis, the CytoScan Dx Assay aids in the identification of underlying genetic causes of neurological and dysmorphic disorders in children. The assay enables users to accurately detect numerous chromosomal variations at higher resolution and greater coverage than conventional methods. It has demonstrated to improve diagnostic yield by an incremental 12.5% compared to G-banded karyotyping.
ChAS Dx is a powerful, intuitive software that simplifies cytogenetic analysis, visualization, and reporting of chromosomal aberrations across the genome. ChAS Dx provides whole-genome support for CytoScan Dx Arrays with flexible parameters and data formats, as well as direct access to multiple leading external genetic databases. The advanced data analysis software is available to all CytoScan Dx customers at no additional cost.
The complete IVDR compliant CytoScan Dx Cytogenetics Suite is a sample to insight solution that includes the CytoScan Dx Array, a reagent kit, the Applied Biosystems™ GeneChip™ System 3000 Dx platform for array processing, and user-friendly ChAS Dx software.
To learn more about the complete IVDR compliant CytoScan Cytogenetics Suite, please visit www.thermofisher.com/microarrayivd.
For In Vitro Diagnostic Use.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530659960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moody’s Agentic Solutions to Automate Complex Workflows and Speed Human Decision-Making16.9.2025 14:00:00 CEST | Press release
Moody’s today announced Agentic Solutions, a groundbreaking addition to its suite of AI-powered offerings designed to transform how organizations make decisions in complex, high-stakes environments. The new solutions empower organizations to act with greater speed, precision, and confidence than ever before, reshaping how risk is decoded, opportunities are identified, and decisions are made. “For over a century, our customers have looked to Moody’s for premium data, trusted insights, and cutting-edge solutions to help them make better, more informed decisions,” said Rob Fauber, President and CEO of Moody’s. “Agentic Solutions is a natural extension of our legacy of investment and innovation – anchored in the strength of our industry leading data-estate and the depth of our people’s analytical skills. By integrating agentic capabilities into the workflows of our customers, we are supercharging the speed and precision at which we can help our customers understand risk and unlock opportun
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran16.9.2025 14:00:00 CEST | Press release
VELA to operate the world’s first sailing cargo trimaran powered by 100 percent wind when at sea1 to sail between Europe and the U.S.Takeda to become the first biopharmaceutical company to ship its products on VELA’s wind-powered trimaran, starting a new era of sustainable shipping in pharma Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using VELA’s first-of-its-kind sailing cargo trimaran. VELA designed and will operate a fleet of new generation sailing cargo vessels, powered 100 percent by wind when at sea. Purpose-built to handle pharmaceutical products, VELA will offer reliable, secure and ultra-low-emission sea freight shipping. The maiden voyage is planned for late 2026. VELA’s new wind-powered sea freight will offer a climate-conscious alternative to other transportation for the pharmaceutical industry – cutting use-relat
Franklin Templeton Forms Strategic Partnership with Copenhagen Infrastructure Partners, DigitalBridge, and Actis to Expand Infrastructure Solutions for Private Wealth16.9.2025 14:00:00 CEST | Press release
Franklin Templeton, a global investment leader with more than $1.6 trillion in assets under management, together with three leading institutional infrastructure investment firms: Actis, the Sustainable Infrastructure business of General Atlantic; Copenhagen Infrastructure Partners (“CIP”); and DigitalBridge, today announced a strategic partnership to deliver private infrastructure solutions to individual investors. This partnership seeks to provide private wealth clients with differentiated access to high-growth infrastructure opportunities, thematically focused on energy security, electrification, and digitalization, as well as sectors including data centers and hyperscaler development, renewable energy, fiber and towers, and digital power. “We are excited to partner with three leading firms: DigitalBridge, CIP, and Actis, in response to a compelling market demand for allocations to infrastructure,” said Jenny Johnson, President and CEO, Franklin Templeton. “The trends shaping the pri
Matrix Executions Unveils White-Label Equity Options Algos: True Customization for Broker-Dealers16.9.2025 13:45:00 CEST | Press release
Matrix Executions, a leader in options trading technology, announced its latest launch of its white-label equity options algorithmic trading solutions. This product empowers broker dealers with true customization and control, enabling them to offer a bespoke algo trading experience to their clients. The product leverages Matrix Executions’ advanced execution algo suite overlayed with the Matrix QRX ATS for an all-in-one answer to execution customization. In today's dynamic market, a one-size-fits-all approach no longer works. Matrix Executions’ offering provides broker dealers with the ability to define, configure, and deploy option algorithms with varying levels of precision. This isn't just a re-skinned product but a foundation for dynamic innovation. The Matrix white-label solution provides extensive bespoke parameter configurations and true customization. Their robust strategy configuration library allows broker-dealers to fine-tune specific variables to optimize performance for di
Tecnotree Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations16.9.2025 13:38:00 CEST | Press release
Tecnotree, a global leader in AI, 5G, and cloud-native digital platforms and services has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916788293/en/ Tecnotree Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI in CSP Customer and Business Operations We feel this underscores the company’s ability to deliver AI-powered, cloud-native platforms that enable communications service providers (CSPs) and enterprises worldwide to accelerate digital transformation, monetize networks, and deliver hyper-personalized customer experiences. The Gartner report, authored by analysts Pulkit Pandey, Amresh Nandan, Will Rice, and Mounish Rai, evaluates leading AI vendors for CSP customer and business operations. According to Gartner, AI in CSP customer and business operations helps CSPs utilize AI/ML to generate ins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom